Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30926135 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPK1L3MBTL1HPGD | |
| SCHEMBL10850393 | 0.68 | PLD1 (0.38) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13749952 | 0.59 | PDPK1 (0.48) | ALDH1A1MAPK1PDPK1 | |
| SCHEMBL9540875 | 0.59 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1HPGDKDM4EGLA | |
| Hydrochloric Acid SCHEMBL29629263 | 0.58 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HPGDKDM4EGLA | |
| SCHEMBL28290659 | 0.57 | HRH4 (0.40) | SMN1; SMN2ALDH1A1L3MBTL1KDM4EGLA | |
| SCHEMBL14960628 | 0.56 | LPO (0.41) | SMN1; SMN2ALDH1A1HPGDKDM4EGLA | |
| SCHEMBL13959674 | 0.55 | PDPK1 (0.44) | PDPK1 | |
| SCHEMBL5366108 | 0.55 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MAPK1L3MBTL1HPGD | |
| SCHEMBL14868885 | 0.55 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1MAPK1L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | SMN1; SMN2 1008/4885ALDH1A1 1661/4885MAPK1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.